Esophageal candidiasis: Difference between revisions
No edit summary |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 21: | Line 21: | ||
==Management== | ==Management== | ||
* Fluconazole 400mg PO loading dose, followed by 200mg PO Qdaily x 2 weeks | * [[Fluconazole]] 400mg PO loading dose, followed by 200mg PO Qdaily x 2 weeks | ||
* Itraconazole 200mg PO Qdaily for 2 weeks | *[[Itraconazole]] 200mg PO Qdaily for 2 weeks | ||
** has more nausea side-effects and drug interactions compared to fluconazole | ** has more nausea side-effects and drug interactions compared to fluconazole | ||
| Line 33: | Line 33: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:ID]] [[Category:GI]] | |||
Revision as of 23:09, 10 September 2016
Background
- Most commonly seen in HIV patients with CD4 count < 100 (AIDS-defining illness) or chronic inhaled glucocorticoid use
Clinical Features[1]
- odynophagia
- dysphagia
- retrosternal pain
- nausea/vomiting
Differential Diagnosis
Esophagitis
- Esophageal candidiasis
- Cytomegalovirus esophagitis
- Herpes Simplex esophagitis
- Eosinophilic esophagitis
- Medication-induced esophagitis
Evaluation
- Thick, white, linear esophageal plaques on endoscopy
Management
- Fluconazole 400mg PO loading dose, followed by 200mg PO Qdaily x 2 weeks
- Itraconazole 200mg PO Qdaily for 2 weeks
- has more nausea side-effects and drug interactions compared to fluconazole
Disposition
See Also
External Links
References
- ↑ Kauffmann CA. Overview of Candida Infections. UptoDate. 2016.